secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANAPTYSBIO, INC (ANAB)
CIK:        0001370053
Form:       8-K
Filed at:   2023-01-05T23:59:59+00:00
Accession:  0001370053-23-000005
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AnaptysBio ends alopecia areata trial; launches Phase 2b for RA and atopic dermatitis
--------------------------------------------------------------------------------

- Rosnilimab Phase 2a in alopecia areata failed to achieve target efficacy (no patient SALT<20); further development discontinued.
- Advancing rosnilimab (PD-1 agonist) into global Phase 2b for rheumatoid arthritis; initiates Q3 2023, top-line mid-2025.
- Advancing ANB032 (BTLA agonist) into global Phase 2b for atopic dermatitis; initiates Q2 2023, top-line year-end 2024.
- Cash and investments >$575M as of Dec 31, 2022; estimated ~4-year runway excluding GSK royalties.
- Rosnilimab second Phase 2 trial in undisclosed indication expected by year-end 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1370053/000137005323000005/0001370053-23-000005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1370053/000137005323000005/anab-20230105.htm
  HTML page:      https://secwatch.observer/filing/0001370053-23-000005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer